The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: A prospective, multicenter, double-blinded, randomized, placebo-controlled trial

Michael G.L. Sarr, Eugene A. Woltering

Research output: Contribution to journalArticle

143 Scopus citations

Abstract

BACKGROUND: Pancreatectomy can be complicated by pancreatic anastomotic leakage, causing major morbidity. STUDY DESIGN: Our aim was to determine if vapreotide, a potent long-acting somatostatin analogue, would decrease pancreas-related complications. This prospective, multicenter, randomized, doubleblind, placebo-controlled trial involved 275 patients without preexisting chronic pancreatitis undergoing elective proximal, central, or distal pancreatectomy. Complications were defined by objective criteria before beginning the study. RESULTS: One hundred thirty-five patients received vapreotide; 140 patients received placebo. There were no statistically significant differences between vapreotide- and placebo-treated patients in either pancreas-related complications (30.4% versus 26.4%, respectively) or in other complications not directly related to the pancreas (40% versus 42%, respectively). CONCLUSIONS: The potent somatostatin analogue vapreotide does not appear to decrease postoperative complications after major pancreatectomy in patients without chronic pancreatitis.

Original languageEnglish (US)
Pages (from-to)556-564
Number of pages9
JournalJournal of the American College of Surgeons
Volume196
Issue number4
DOIs
StatePublished - Apr 1 2003

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: A prospective, multicenter, double-blinded, randomized, placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this